How I Treat: Secondary Acute Myeloid Leukemia
SD Green, ES Wang - Blood Journal, 2024 - ashpublications.org
Secondary acute myeloid leukemia (sAML) has traditionally been used to designate any
AML disease arising from an antecedent hematologic disorder or following prior cytotoxic or …
AML disease arising from an antecedent hematologic disorder or following prior cytotoxic or …
Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis
S Cao, Q Tao, J Wang, Q Zhang, Y Dong - Medicine, 2023 - journals.lww.com
Background: To ascertain the efficacy and safety of cladribine, cytarabine, and filgrastim-
based regimen in relapsed or refractory (R/R) AML patients. Methods: Clinical studies were …
based regimen in relapsed or refractory (R/R) AML patients. Methods: Clinical studies were …
Management and outcomes of blast transformed chronic myelomonocytic leukemia
D Hammond, G Montalban-Bravo - Current hematologic malignancy …, 2021 - Springer
Abstract Purpose of Review Despite recent advances in the treatment of de novo acute
myeloid leukemia (AML), AML arising from antecedent chronic myelomonocytic leukemia …
myeloid leukemia (AML), AML arising from antecedent chronic myelomonocytic leukemia …
[引用][C] Advances in Nanoparticles for Skin Protection—A Review
Nanoparticles (NPs) have revolutionized the field of skin protection and treatment by offering
unique properties that enhance drug delivery, efficacy and safety. This review explores the …
unique properties that enhance drug delivery, efficacy and safety. This review explores the …